Working... Menu
Trial record 37 of 2401 for:    Diabetes | "Diabetes Mellitus, Insulin-Dependent"

Beta Cell Function in (Pre) Type 1 Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00800085
Recruitment Status : Unknown
Verified December 2013 by Bart Keymeulen, AZ-VUB.
Recruitment status was:  Enrolling by invitation
First Posted : December 1, 2008
Last Update Posted : December 30, 2013
Information provided by (Responsible Party):
Bart Keymeulen, AZ-VUB

Brief Summary:
This study will establish criteria indicating short-term loss of beta cell mass and therefore accelerated progression towards type 1 diabetes.

Condition or disease Intervention/treatment Phase
Type 1 Diabetes Drug: glucose 20% Phase 1 Phase 2

Detailed Description:
This study will establish criteria indicating short-term loss of beta cell mass and therefore accelerated progression towards type 1 diabetes. These criteria may help to determine the time point and type of prevention may contribute to the composition of homogeneous groups of study subjects (based on residual beta cell mass, homogeneous risk of beta cell destruction during intervention) and may lead to the identification of functional markers that could be used as surrogate endpoints. This may reduce the number of subjects needed to treat as well as the follow-up time necessary to study significant effects of the test substance.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: Beta Cell Function in (Pre) Type 1 Diabetes
Study Start Date : October 2006
Estimated Primary Completion Date : October 2014
Estimated Study Completion Date : October 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Diabetes Type 1
Drug Information available for: Dextrose

Arm Intervention/treatment
No Intervention: FDR of type 1 diabetes patients receiving glucose 20%
First Degree Relatives of diabetes type 1 patient with a high, intermedian or low risk (accoring to the criteria of the protocol), for developing diabetes type 1.
Drug: glucose 20%
maintain glycemia at 180 mg/dL till 150 min. after start glucose infusion: with a maintenance dose computed at 5- to 10-minute intervals

Primary Outcome Measures :
  1. The systematic and simultaneous determination of markers of functional beta cell mass and immune status allows stratification according to the stage of the pathogenic process rather than according to a late metabolic consequence of this process [ Time Frame: 48 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   5 Years to 40 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • The following groups of first degree relatives of type1 diabetes patients with normal glucose tolerance during OGTT (5-39 years) will be included after informed consent on the basis of their antibody status (n = 40 per group):

    • IA-2A-positives;
    • Ab.-positives (positive for at least 2 different Abs. (IAA, GADA and/or ICA) and/or persistently Ab.-positive for 1 of these Abs;
    • persistently Ab.-negatives.
  • 40 type 1 diabetes patients with the following criteria will be studied: 1) aged 12-39 years; 2) < 4 weeks of insulin treatment; 3) auto-Ab.-positive; 4) polyuria since < 6 months; 5) < 10% weight loss over the last 6 months; 6) informed consent.

Exclusion Criteria:

  • Pregnancy or lactation in women
  • Use of illicit drugs or overconsumption of alcohol (> 3 beers/day) or history of drug or alcohol abuse
  • Being legally incapacitated, having significant emotional problems at the time of the study, or having a history of psychiatric disorders
  • Having received antidepressant medications during the last 6 months
  • Treatment with immune modulating or diabetogenic medication (such as corticosteroids)
  • Presently participating in another clinical study
  • History of any illness that, in the opinion of the investigator, might confound the results of the study or pose additional risks to the subjects

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00800085

Layout table for location information
Universitair Ziekenhuis Antwerpen
Antwerpen, Belgium
UZ Brussels
Brussels, Belgium, 1090
UZ Gent
Gent, Belgium, 9000
UZ Leuven
Leuven, Belgium, 3000
Sponsors and Collaborators
Layout table for investigator information
Principal Investigator: katelijn Decochez, MD PhD UZ Brussels


Layout table for additonal information
Responsible Party: Bart Keymeulen, MD PhD, AZ-VUB Identifier: NCT00800085     History of Changes
Other Study ID Numbers: KD_BF_01
First Posted: December 1, 2008    Key Record Dates
Last Update Posted: December 30, 2013
Last Verified: December 2013

Keywords provided by Bart Keymeulen, AZ-VUB:
first degree relatives of type 1 diabetes patients
hyperglycemic clamp test

Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases